摘要
目的探讨应用FOLFOX4方案化疗联合射频消融（RFA）治疗伴有门脉癌栓的局部晚期原发性肝癌的疗效。方法 46例经临床确诊伴有门脉癌栓的局部晚期原发性肝癌患者随机分为两组,联合组（n=24）：此组患者先行RFA治疗,每4周治疗1次,共4个疗程,第1次RFA治疗后1周行FOLFOX4方案化疗,14 d为1个周期,共12个周期;单纯射频组（n=22）：此组患者单纯采用射频消融治疗,每4周治疗1次,共4个疗程。观察终点为病情进展。结果联合组患者治疗后1、2、3年无瘤生存率分别为75.2%、51.0%和36.1%,射频组患者治疗后1、2、3年无瘤生存率分别为60.0%、31.2%和15.7%,差异有统计学意义（P=0.024）。结论对于肿瘤直径为3～5 cm的多个病灶结节合并门脉癌栓的原发性肝癌患者,FOLFOX4方案化疗联合射频消融治疗的疗效优于单纯射频消融。
Objective To compare the effect of chemotherapy of FOLFOX 4 combined with radiofrequency ablation（RFA） and radiofrequency ablation alone for the treatment of 3～5 cm hepatocellular carcinoma（HCC） with portal vein tumor thrombus. Methods Choosing 46 cases of clinically diagnosed locally advanced hepatocellular carcinoma with portal vein tumor thrombus patients and randomly dividing them into two groups, FOLFOX 4 combined with RFA group（n=24）： first with RFA therapy, once every 4 weeks, a total of 4 sessions, first week after RFA treatment with FOLFOX 4 chemotherapy, 14 days for a cycle, a total of 12 cycles; RFA alone group（n =22）： patients treatment with RFA alone, once every 4 weeks, a total of 4 sessions. Observed disease progression. Results Disease free survival of FOLFOX 4 combined with RFA group after 1 year, 2 year, 3 year were 75.2%, 51.0%, and 36.1%, and RFA alone group were 60.0%, 31.2% and 15.7%. The differences between the two groups were statistically significant（P=0.024）. Conclusion Chemotherapy of FOLFOX 4 plus RFA are better than RFA alone for the treatment of 3～5cm hepatocellular carcinoma with portal vein tumor thrombus.
出处
《中国实用医药》
2014年第15期13-15,共3页
China Practical Medicine
关键词
原发性肝癌
化疗
射频消融
Hepatocellular carcinoma
Chemotherapy
Radiofrequency ablation
